ANG Lifesciences India Limited (ANG.BO)
INR 45.93
(-1.12%)
INR 45.93
(-1.12%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -196.07 Million | 263.77 Million | 247.17 Million | 91.43 Million | 48.3 Million | 74.62 Million |
| Net Income | -101.43 Million | 26.25 Million | 535 Million | 70.27 Million | 60.95 Million | 56.48 Million |
| Depreciation & Amortization | 83.71 Million | 93.53 Million | 58.75 Million | 13.16 Million | 12.28 Million | 11.23 Million |
| Deferred income taxes | - | - | - | -685.54 Thousand | -893.87 Thousand | 274.06 Thousand |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -52.67 Million | 65.14 Million | -450.52 Million | -20.97 Million | -50.18 Million | -16.8 Million |
| Other non-cash items | -35.65 Million | 78.84 Million | 103.94 Million | 29.65 Million | 28.67 Million | 23.42 Million |
| Investing Cash Flow | 193.64 Million | -93.25 Million | -444.09 Million | -76.95 Million | -16.56 Million | -7.71 Million |
| Investments in PPE | -55.68 Million | -104.44 Million | -413.44 Million | -42.44 Million | -16.42 Million | -8.41 Million |
| Acquisitions | 244.95 Million | - | - | - | - | - |
| Investment purchases | - | - | -34.33 Million | -35 Million | - | - |
| Sales/Maturities of investments | 4.36 Million | 4.52 Million | - | - | - | - |
| Other Investing Activities | 254.6 Million | 6.66 Million | 3.68 Million | 492 Thousand | -144.8 Thousand | 700.64 Thousand |
| Financing Cash Flow | 2.37 Million | -170.74 Million | 199.27 Million | -11.86 Million | -39.45 Million | -37.98 Million |
| Debt repayment | -13.06 Million | -70.15 Million | -289.21 Million | -21.75 Million | -27.52 Million | -18.35 Million |
| Dividends payments | - | - | -10.35 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 20 Million | - | - | - | - |
| Other Financing Activities | -147.31 Million | -120.58 Million | 498.84 Million | 9.89 Million | -11.92 Million | -19.62 Million |
| Accounts receivables | 114.21 Million | 179.31 Million | -452.18 Million | -126.79 Million | -43.15 Million | -95.98 Million |
| Accounts payables | -44.02 Million | -22.21 Million | 253.3 Million | 142.5 Million | 39.75 Million | -5 Million |
| Inventory | 7.21 Million | -115.28 Million | -177 Million | -92.54 Million | -34.66 Million | 12.05 Million |
| Other working capital | -130.07 Million | 23.32 Million | -74.64 Million | 55.85 Million | -12.1 Million | 72.12 Million |
| Cash at beginning of period | 3.24 Million | 3.46 Million | 1.11 Million | 36 Million | 43.71 Million | 14.79 Million |
| Cash at end of period | 57.35 Million | 3.24 Million | 3.46 Million | 38.62 Million | 36 Million | 43.71 Million |
| Capital Expenditure | -55.68 Million | -104.44 Million | -413.44 Million | -42.44 Million | -16.42 Million | -8.41 Million |
| Effect of forex changes on cash | - | - | - | - | - | -1.00 |
| Net cash flow / Change in cash | 54.11 Million | -218 Thousand | 2.34 Million | 2.62 Million | -7.7 Million | 28.92 Million |
| Free Cash Flow | -251.75 Million | 159.32 Million | -166.27 Million | 48.99 Million | 31.88 Million | 66.2 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -30.73 Million | -101.43 Million | -36.46 Million | -59.31 Million | -23.17 Million | 17.52 Million |
| Depreciation & Amortization | - | 83.71 Million | - | 19.14 Million | 22.22 Million | 21.88 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -52.67 Million | - | - | - | - |
| Other non-cash items | 30.73 Million | -35.65 Million | 36.46 Million | 59.31 Million | 23.17 Million | -17.52 Million |
| Investing Cash Flow | - | 193.64 Million | - | - | - | - |
| Investments in PPE | - | -55.68 Million | - | - | - | - |
| Acquisitions | - | 244.95 Million | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | 4.36 Million | - | - | - | - |
| Other Investing Activities | - | 254.6 Million | - | - | - | - |
| Financing Cash Flow | - | 2.37 Million | - | - | - | - |
| Debt repayment | - | -13.06 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -147.31 Million | - | - | - | - |
| Accounts receivables | - | 114.21 Million | - | - | - | - |
| Accounts payables | - | -44.02 Million | - | - | - | - |
| Inventory | - | 7.21 Million | - | - | - | - |
| Other working capital | - | -130.07 Million | - | - | - | - |
| Cash at beginning of period | - | 3.24 Million | - | 14.35 Million | 37.52 Million | 3.24 Million |
| Cash at end of period | - | 57.35 Million | - | 52.63 Million | 14.35 Million | 17.52 Million |
| Capital Expenditure | - | -55.68 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 54.11 Million | - | 38.28 Million | -23.17 Million | 14.27 Million |
| Free Cash Flow | - | -251.75 Million | - | 38.28 Million | -23.17 Million | 17.52 Million |
FMNB
RCOM
CDIX
ARQT
SMR-WT
BSPM